Skip to content

A novel role for remifentanil: the reversal of established capsaicin-induced hyperalgesia.

A novel role for remifentanil: the reversal of established capsaicin-induced hyperalgesia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-004549-14-AT
Enrollment
Unknown
Registered
2008-01-23
Start date
2008-02-15
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This is a volunteer study in healthy volunteers. Pain research, reversal of hyperalgesia by IMP is studied.

Interventions

Sponsors

Department of Anaesthesie, General Intensive Care and Pain Therapy, Medical University of Vienna
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Men or women, aged between 19 and 40 years Body mass index between 15th and 85th percentile Normal findings in the medical history and physical examination Drug free for 1 week prior to the study day Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy any disease ongoing pain older than 40 years old

Design outcomes

Primary

MeasureTime frame
Main Objective: To study the reversal of established hyperalgesia. The main outcome variable will be: area of pin prick hyperalgesia.;Primary end point(s): Area of pin prick hyperalgesia 6 hours after stop of IMP;Secondary Objective: To study the reversal effect on additional outcome variables for mechanical hyperalgesia will be: stimulus-response (SR)-function to a set of modified rigid von Frey filaments (8 -512 mN), area of dynamic allodynia to brush and SR-function to dynamic mechanical stimuli. Pain immediately after injection and heat pain threshold within the area of mechanical hyperalgesia will serve as additional outcome variables.

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026